Osimertinib (AZD9291)

For research use only. Not for use in humans.

製品コードS7297 別名：Mereletinib

CAS No. 1421373-65-0

Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

サイズ

価格(税別)

5mg	JPY 18100
10mg	JPY 24400
100mg	JPY 118200

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(221)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

製品説明

特性

Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

ターゲット

L858R/T790M EGFR ^[1] (LoVo cells)	Exon 19 deletion EGFR ^[1] (LoVo cells)	WT EGFR ^[1] (LoVo cells)
11.44 nM	12.92 nM	493.8 nM

体外試験

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. ^[2]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PC-9/BRc1	M1;ZSWZ2dmO2aX;uJGF{e2G7	M2\CUlUxKG6P	NYjaOmN1OjRiaB?=	NUPsPWdyTE2VTx?=	NI\oRZFqdmS3Y3XzJIV5eHKnc4Ppc44hd2ZidHjlJJBzd2Gyb4D0c5Rq[yCEQ1ytNkBn[W2rbImgcYVu[mW{IFLJUS=>	NXLqTZBvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/ERc1	M2T6fmZ2dmO2aX;uJGF{e2G7	NFyxXY82OCCwTR?=	M2HPN\|I1KGh?	MWjEUXNQ	NV7UfZd6cW6mdXPld{BmgHC{ZYPzbY9vKG:oIITo[UBxem:jcH;weI91cWNiQlPMMVIh\mGvaXz5JI1mdWKncjDCTW0>	NHLHbnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|MzPSd-MkW0O\|c{OjV:L3G+
VP-2	NXnmXmp3TnWwY4Tpc44hSXO\|YYm=	NWmz[G42PTBibl2=	MV:yOEBp	NWjsS4xlTE2VTx?=	M{nlU4lv\HWlZYOg[ZhxemW\|c3nvckBw\iC2aHWgdJJw[XCxcITveIlkKEKFTD2yJIZidWmueTDt[Y1j\XJiQlnN	NVjvZ3RzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/BRc1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfPOVAhdk1?	NY\5[XVNOTBiZB?=	M4rwRWROW09?	M1vQOolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gcI9v\y22ZYLtJEgyOC2mYYmpJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7cx?=	NXu3bldFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/ERc1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXu1NEBvVQ>?	NXjYOllGOTBiZB?=	NXS4eW1XTE2VTx?=	MX7pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHzvcocufGW{bTCoNVAu\GG7KTDndo94fGhiaX7obYJqfGmxbjDhd5NigXN?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
VP-2	Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVq1NEBvVQ>?	NFfnSVQyOCCm	NUe0SmpxTE2VTx?=	MorzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm\|	NUT6fWVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC9 GR4	Ml;3SpVv[3Srb36gRZN{[Xl?	NUjwV\|ZiOC1zMDFOwG0>	MUW3NkBp		MVnpcohq[mm2c9MgSWdHWiCyaH;zdIhwenmuYYTpc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7nxsA>	M3j5XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9	NUX2RWxnTnWwY4Tpc44hSXO\|YYm=	NX3CXJNROC1zMDFOwG0>	MUW3NkBp		NY\Qb3dlcW6qaXLpeJMhX1RiRVfGVkBifCCub4egZ49v[2WwdILheIlwdnN?	NV;icHJzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFg3OzNpPkK1PVQ5PjN\|PD;hQi=>
PC9 GR4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjC[ZFMOC1zMDFOwG0>	MkTxO\|IhcA>?		MlfIbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	MofxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N\|MoRjJ3OUS4OlM{RC:jPh?=
BAF3	MXPGeY5kfGmxbjDhd5NigQ>?		M{jYOVczKGh?		NWTY[YpET0l3MDC9JFAvODByMzFOwG0>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	M1LQWGZ2dmO2aX;uJIF{e2G7		M1fVXlczKGh?		MWfHTVUxKD1iMD6wNFA{KM7:TR?=	Mmr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BAF3	NUTWNlc1TnWwY4Tpc44h[XO\|YYm=		NVnNO3dTPzJiaB?=		MXfHTVUxKD1iMD6wNFEh\|ryP	NWG5dGR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	NXv3W4JxTnWwY4Tpc44h[XO\|YYm=		NG\jUHk4OiCq		MoPtS2k2OCB;IECuNFAyKM7:TR?=	NXq0T21xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9	NIK3NVhHfW6ldHnvckBie3OjeR?=		NYDVPVF6PzJiaB?=		MU\HTVUxKD1iMD6wNFIh\|ryP	NWLSXWJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	NGHJ[HFHfW6ldHnvckBie3OjeR?=		MnTKOEBp		MWTFR\|UxKD1iMD6wNFIh\|ryP	NHLtXHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	M{HOcGZ2dmO2aX;uJIF{e2G7		NULQUosyOyCq		Mk\rTWM2OCB;IECuNFAzPSEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR\|M{iyPUc,Ojd2M{O4Nlk9N2F-
H1975	MoXGSpVv[3Srb36gZZN{[Xl?		M4\mSVMhcA>?		NFXyTmtKSzVyIE2gNE4xODJ3IN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR\|M{iyPUc,Ojd2M{O4Nlk9N2F-
H3255	M17VXGZ2dmO2aX;uJIF{e2G7		NFzUSGc{KGh?		NHTrc2pKSzVyIE2gNE4xODRzIN88US=>	M1ywTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN\|gzQTxxYU6=
NCI-H1975	NVi0U2kxTnWwY4Tpc44h[XO\|YYm=		NH7ZcVU4OiCq		NIH4S\|JIUTVyIE2gNE4xODVizszN	NYK0XGR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9	NEDqXoZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M4[0VVczKGh?		MmjaTWM2OCB;IECuNFA3PSEQvF2=	M2PXO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G2OlQyLz5{OEexOlY1OTxxYU6=
NCI-H1975	NHnHU3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NEWze\|Q4OiCq		NV3pNnZKUUN3MDC9JFAvODFyNTFOwG0>	NG\ZOlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOlY1OSd-Mki3NVY3PDF:L3G+
Sf21	MYrGeY5kfGmxbjDhd5NigQ>?				M4nDUGlEPTBiPTCwMlAyOiEQvF2=	MlvxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OU[yOlcoRjJ5OUm2NlY4RC:jPh?=
PC9-DRH	NGrTV\|VHfW6ldHnvckBie3OjeR?=		MVuyJIg>		M3PkTWlEPTBiPTCwMlAyOyEQvF2=	NFjxe5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
BAF3	NFvITFJHfW6ldHnvckBie3OjeR?=		NUjlSmg1PzJiaB?=		NHTF[FJIUTVyIE2gNE4xOTNizszN	M1nHfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	M1XKemZ2dmO2aX;uJIF{e2G7		NXXhcG1lQTZiaB?=		Mk\jSWM2OCB;IECuNFE1KM7:TR?=	M1HsT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
HCC827	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NUX3SZh7QTZiaB?=		M3HEXGVEPTBiPTCwMlAyPCEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
NCI-H1975	NEfuVphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NIj0RoY6PiCq		M1LyO2VEPTBiPTCwMlAyPCEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
NCI-H1975	MnfNSpVv[3Srb36gZZN{[Xl?		NEfSPXQzKGh?		NIjLN\|lKSzVyIE2gNE4xOTVizszN	Mlv6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
H1975	MkfoSpVv[3Srb36gZZN{[Xl?		Mm[yNkBp		NILrbYNKSzVyIE2gNE4xOTVizszN	NFq2cIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm2PFI2Oyd-Mk[5OlgzPTN:L3G+
PC9	NUD2Nnc4TnWwY4Tpc44h[XO\|YYm=		NH\FZ3gzKGh?		NYHoN\|BGUUN3MDC9JFAvODF5IN88US=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
NCI-H1975	NHTWbopCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NHrtcIg4OiCq		M1zUeWlEPTBiPTCwMlAyQSEQvF2=	M1;nd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[2O\|c{Lz5{OUS2Olc4OzxxYU6=
NCI-H1975	MnTWSpVv[3Srb36gZZN{[Xl?		NEjndZk6PiCq		MoS4SWM2OCB;IECuNFE6KM7:TR?=	MknYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkWyOlkoRjJ6MkK1NlY6RC:jPh?=
NCI-H1975	NVeyb3VjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NVrwd2FIQTZiaB?=		M3K2c2VEPTBiPTCwMlAyQSEQvF2=	NF\PWZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[wN\|k6OSd-Mki2NFM6QTF:L3G+
NCI-H1975	NFvEPINCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NUfHc\|lIPzJiaB?=		NULT[no1UUN3MDC9JFAvODF7IN88US=>	MmqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN\|QxRC:jPh?=
HCC827	M{jTNmZ2dmO2aX;uJIF{e2G7		NWLTeoF4OiCq		NIfCUmxKSzVyIE2gNE4xOjNizszN	NXWxdFJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
NCI-H1975	NXr5OllMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MmjzO\|IhcA>?		NWi0PZN[UUN3MDC9JFAvODJ\|IN88US=>	MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5NlYoRjJ7NUO0PVI3RC:jPh?=
PC9	MWPDfZRwfG:6aXPpeJkh[XO\|YYm=		NH;WfmQ4OiCq		M3zHbmdKPTBiPTCwMlAzOyEQvF2=	Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
NCI-H1975	MW\DfZRwfG:6aXPpeJkh[XO\|YYm=		NEHTfYk4OiCq		MkHjS2k2OCB;IECuNFI1KM7:TR?=	M3PGOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
HCC827	NVfGSHBGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MYK3NkBp		MlLKTWM2OCB;IECuNFI2PCEQvF2=	NF:1RYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW3OlI4Oid-Mkm1O\|YzPzJ:L3G+
HCC827	NH:2RWFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NV7zS3NpPzJiaB?=		M1v5R2lEPTBiPTCwMlAzPyEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O\|M9N2F-
HCC827	M1PKRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NIXJN5E4OiCq		M4\TXWlEPTBiPTCwMlAzPyEQvF2=	NIf6WHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N\|M1OCd-Mkm4OVM{PDB:L3G+
NCI-H1975	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NHfrNYQ4OiCq		NVu1[oY2UUN3MDC9JFAvODNizszN	M3;TXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEOzOVc6Lz5{OECzN\|U4QTxxYU6=
H3255	NIrvcIVHfW6ldHnvckBie3OjeR?=		NVG0T5B6PzJiaB?=		MX7HTVUxKD1iMD6wN\|Mh\|ryP	NW\vOHN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H3255	NYXEPVczTnWwY4Tpc44h[XO\|YYm=		MWCyJIg>		NXPacHJzUUN3MDC9JFAvODN4IN88US=>	M3fWXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
NCI-H1975	NVS5boxoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NXPYWIgxPzJiaB?=		M{\rVGlEPTBiPTCwMlA1OSEQvF2=	NXriRohbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|AyQTJpPkK5O\|MxOTl{PD;hQi=>
NCI-H1975	M2XmdWZ2dmO2aX;uJIF{e2G7		M1jBRlEhcA>?		MVPJR\|UxKD1iMD6wOFEh\|ryP	NI\QU2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N\|Q6OjZ:L3G+
BAF3	MUDGeY5kfGmxbjDhd5NigQ>?		NH3Zb\|Q1KGh?		NH3XbppGSzVyIE2gNE4xPDNizszN	M{m1WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975	NE\XNIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NXv3TI1PPzJiaB?=		NGTJOm1KSzVyIE2gNE4xPDd{IN88US=>	NYrrZZlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O\|YzPzJpPkK5OVc3Ojd{PD;hQi=>
NCI-H1975	NHnkcoNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MVq3NkBp		M3HMR2lEPTBiPTCwMlA2OiEQvF2=	NHzrZ4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVY{QSd-MkexN\|E3Ozl:L3G+
PC9	M2DiRWZ2dmO2aX;uJIF{e2G7		MonsNkBp		MonHTWM2OCB;IECuNFU3KM7:TR?=	NIWyTYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
NCI-H1975	NFP3Z\|VEgXSxdH;4bYNqfHliYYPzZZk>		NEPGdlg4OiCq		M4L1W2lEPTBiPTCwMlA3KM7:TR?=	M13neVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEi2PVU{Lz5{OUS4Olk2OzxxYU6=
HCC827	Ml;QRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				NXrOcIM{UUN3MDC9JFAvODZzNjFOwG0>	M1XXZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
NCI-H1975	M2fPdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				NEjZPFFKSzVyIE2gNE4xPjdizszN	M2TIclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
HaCaT	MYHGeY5kfGmxbjDhd5NigQ>?		NUX5Z2JZOyCq		M1fGR2lEPTBiPTCwMlA4OzdizszN	NUP2XlJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0N\|M5OjlpPkK3OFM{QDJ7PD;hQi=>
NCI-H1975	M2HSS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NELZRnM4OiCq		M17HdGlEPTBiPTCwMlE{KM7:TR?=	MlP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
A431	MlrXSpVv[3Srb36gZZN{[Xl?		NWW2epg5OSCq		NUTESY05UUN3MDC9JFAvOTRzIN88US=>	NWPDTIZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
A549	NH7pVmRHfW6ldHnvckBie3OjeR?=				NX2yW3dGUUN3MDC9JFAvOTVizszN	M{X0bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
Calu3	MYXDfZRwfG:6aXPpeJkh[XO\|YYm=		NWCxZWNuPzJiaB?=		MWHHTVUxKD1iMD6yOlQh\|ryP	M{eyZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
Sf9	MoDjSpVv[3Srb36gZZN{[Xl?		NIXG[mYzOCCvaX7z		NUfJToJFUUN3MDC9JFAvOjd6IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR6MkG1NUc,Ojh2OEKxOVE9N2F-
BAF3	NGrFc2JHfW6ldHnvckBie3OjeR?=		MWC3NkBp		NYLz[m55T0l3MDC9JFAvOyEQvF2=	NVXSeGhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	NGXsUYRHfW6ldHnvckBie3OjeR?=		NGDOUnI4OiCq		MlrKS2k2OCB;IECuN\|Eh\|ryP	M2\PXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H460	MkfYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MUe3NkBp		MmSwTWM2OCB;IECuOFE2QSEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
LoVo	M4fIfGZ2dmO2aX;uJIF{e2G7		NHXkbIwzKGh?		NWW0NXV{UUN3MDC9JFAvPDhizszN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
LoVo	NYP0NGJKTnWwY4Tpc44h[XO\|YYm=		MXWyJIg>		NXq0RmxWUUN3MDC9JFAvPDhizszN	NIrx[5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OlI3Pyd-Mke5PVYzPjd:L3G+
A549	M4LBU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M{XLflczKGh?		NYDFPIt2UUN3MDC9JFAvPDh4IN88US=>	MnXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO\|IoRjJ7NUe2NlczRC:jPh?=
BAF3	NVK0V4xETnWwY4Tpc44h[XO\|YYm=		NYP5XIdxPzJiaB?=		M1v4eWdKPTBiPTCwMlUh\|ryP	M33XS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A549	NEnvV\|dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MX:3NkBp		NH;UeJdKSzVyIE2gNE42OyEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O\|M9N2F-
A549	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		NWe5XllzPzJiaB?=		NH3y[YlKSzVyIE2gNE42OyEQvF2=	NXjVRW93RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVM{PDBpPkK5PFU{OzRyPD;hQi=>
BAF3	NFG4OmlHfW6ldHnvckBie3OjeR?=		NF7tZZU4OiCq		MkX0S2k2OCB;IECuOVUh\|ryP	NYTQO3pHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	MXzGeY5kfGmxbjDhd5NigQ>?		NHPF[Fk4OiCq		NWjMWow5T0l3MDC9JFAvPTZizszN	NYnP[JVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HEK293	M{S0dmZ2dmO2aX;uJIF{e2G7				MWHJR\|UxKD1iMD61O{DPxE1?	M4Xwe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
BAF3	MljoSpVv[3Srb36gZZN{[Xl?		MmTwO\|IhcA>?		Mkf0S2k2OCB;IECuOVkh\|ryP	MmrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
A431	NITKeZNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=				NGH2[HJKSzVyIE2gNE43OTV4IN88US=>	MkX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
HT-29	MlT5R5l1d3SxeHnjbZR6KGG\|c3H5		NGrI[mo4OiCq		MXrJR\|UxKD1iMD62OUDPxE1?	NUPLW5FCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV\|PD;hQi=>
A431	NFfhWYxHfW6ldHnvckBie3OjeR?=		MUm5OkBp		Mkm3SWM2OCB;IECuOlY4KM7:TR?=	M{\v[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
A431	NYfLToNjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NFfkcYg6PiCq		M1XOTmVEPTBiPTCwMlY4KM7:TR?=	M3HFW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
A431	NX7zXJpUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M4XvWFczKGh?		NVfSWXR4UUN3MDC9JFAvPjh3IN88US=>	NFfLTZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N\|Q6OjZ:L3G+
A431	NFrBd2JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NY[yVJR3QTZiaB?=		M3PaVWVEPTBiPTCwMlch\|ryP	MlniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4MEO5PVEoRjJ6NkCzPVkyRC:jPh?=
A549	NH3VfZREgXSxdH;4bYNqfHliYYPzZZk>		Mle0O\|IhcA>?		NIPoO2pKSzVyIE2gNE45PyEQvF2=	NV3DeJpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV\|PD;hQi=>
A431	M4ntbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWe3NkBp		NEXDVllKSzVyIE2gNE45QTNizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MU[zPUc,OjdzM{G2N\|k9N2F-
BA/F3	M17sbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MmizO\|IhcA>?		MXnJR\|UxKD1iMTFOwG0>	M2naNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BAF3	NGLRZ4VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXSwdW16PzJiaB?=		MXnHTVUxKD1iMT6yJO69VQ>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H2122	NVH6RZQ6TnWwY4Tpc44h[XO\|YYm=		NUTUNZdGPzJiaB?=		NU\vNWZFT0l3MDC9JFEvOiEQvF2=	NGPX[\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A431	NFvwXpdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NV\UenJLPzJiaB?=		NYriW5VkUUN3MDC9JFEvOjRizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
A431	NUTyXFFoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NIXFS4o4OiCq		MUHJR\|UxKD1iMT6yOkDPxE1?	M13FSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
A431	Mkj3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M4m4VVczKGh?		MXXJR\|UxKD1iMT62NFQh\|ryP	Ml\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{O1O\|koRjJ6MEOzOVc6RC:jPh?=
A549	NGjRcIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M3fzTFk3KGh?		NWrRVHdLTUN3MDC9JFEvQDNizszN	M3vSblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
CHL	NHTNe5lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnXGO\|IhcA>?		MmC0S2k2OCB;IEKuPUDPxE1?	MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H1355	NIDpe49HfW6ldHnvckBie3OjeR?=		M{DwS\|czKGh?		M4HMTGdKPTBiPTCzJO69VQ>?	MmXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H1703	MULGeY5kfGmxbjDhd5NigQ>?		NV;ifIVrPzJiaB?=		Mm\OS2k2OCB;IEOuOUDPxE1?	NFfVVIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A549	MnXLSpVv[3Srb36gZZN{[Xl?		NYPmNVlrPzJiaB?=		NEPoVphIUTVyIE2gN{42KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
CHO	MkLpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmLBO\|IhcA>?		NUjVRZlrT0l3MDC9JFQvOiEQvF2=	M{TufFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3	M3PvfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MUO3NkBp		M4TVXmlEPTBiPTC0MlYyKM7:TR?=	NX;Dc3RKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
BAF3	MlziRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NYDG[HdIPzJiaB?=		NIfubHpKSzVyIE2gOU4yPSEQvF2=	NFnmb\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
BEAS2B	M2nLOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NVnKT3E6PzJiaB?=		NUS4VmF{UUN3MDC9JFE1NjlizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
NCI-H1975	NYDwSlRMTnWwY4Tpc44h[XO\|YYm=		NHLGSGIzKGh?		NIG1emtKSzVyIE2gNVUh\|ryP	NXfpZ5FWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
PC9	MWLGeY5kfGmxbjDhd5NigQ>?		MWOyJIg>		MkPyTWM2OCB;IEG3JO69VQ>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
LoVo	M3S2XGZ2dmO2aX;uJIF{e2G7		M3LvfFIhcA>?		MUTJR\|UxKD1iNEiwJO69VQ>?	NIHNS\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
NCI-H1975	MnzGRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				NV2zNY1mSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q6PzCPIHTveYJt\SCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCB{LkWgcYcwc2dxZHH5MEBxdyCzZDDmc5IhPyCmYYnzJJJmdGG2aY\lJJRwKGOxboTyc4w>	NH\t[2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
rat hepatocytes	NWD4OlJJTnWwY4Tpc44h[XO\|YYm=				NF\KbmVKdnS{aX7zbYMh[2ynYYLhcoNmKGmwIILheEBp\XCjdH;jfZRmeyCvZXHzeZJm\CCyZYKgNVAoPiClZXzsdy=>	NVTicHhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
human hepatocytes	MXPGeY5kfGmxbjDhd5NigQ>?				NVjyOoE1UW62cnnud4lkKGOuZXHyZY5k\SCrbjDoeY1idiCqZYDheI9kgXSnczDt[YF{fXKnZDDw[ZIhOTBpNjDj[Yxtew>?	MlfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
NCI-H1975	NU\KcGgySW62aYT1cY9zKGGldHn2bZR6KGG\|c3H5				MX\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEm3NG0h\G:3YnzlJI12fGGwdDD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUhdWdxa3ev[IF6NCCybzDx[EBnd3JiNzDkZZl{KHKnbHH0bZZmKHSxIHPvcpRzd2x?	M{fVdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975	Mn6xSpVv[3Srb36gZZN{[Xl?				MmrNV4Vt\WO2aY\peJkhcW6mZYisJJJifGmxIH;mJGlEPTBiZn;yJGVITlJiVEe5NG0wVDh3OGKg[I92[mynIH31eIFvfCCneIDy[ZN{cW6pIHj1cYFvKE6FST3INVk4PSClZXzsd{B1dyCLQ{WwJIZweiC5aXzkJJR6eGViRVfGVkBmgHC{ZYPzbY5oKGi3bXHuJGE1OzFiY3XscJM>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
NCI-H1975	MY\BcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				MVjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDFS2ZTKFR5OUDNM2w5PTiUIHTveYJt\SCvdYThcpQh\XiycnXzd4lv\yCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgfIVvd2e{YX\0[YQhcW5iQlHMRk9kKGG2aIntbYMhdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCxNEBu\y:tZzygdI8h[mmmIH\vdkAzOSCmYYnz	M2rpTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
HCC827	NIPMRnVCeG:ydH;zbZMh[XO\|YYm=				NG\B[I5KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3NUF5NUCg[IVt\XSrb36gcZV1[W62IHHzd4V{e2WmIHHzJIViemy7IHHwc5B1d3SrYzDj[YxteyCjdDCzJJVOKGGodHXyJFI1KGi{czDifUBCdm6neHnuJHYuTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5JEhTfmJiPTCxMlM1LSl?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O\|M9N2F-
HCC827	M{\veWFxd3C2b4Ppd{Bie3OjeR?=				MoDpTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiRUe0Ok1CPzVyIHTlcIV1cW:wIH31eIFvfCCjc4Pld5Nm\CCjczDsZZRmKGGyb4D0c5Rq[yClZXzsd{BifCB\|IIXNJIFnfGW{IEK0JIhzeyCkeTDBco5mgGmwIG[tSmlVSy:ycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7IDjSeoIhRSB{Nz6xOEUq	NHzDb2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
A549	Mk\oSpVv[3Srb36gZZN{[Xl?				NULYUHh5W2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hSTV2OTDj[YxteyCneIDy[ZN{cW6pIIfpcIQufHmyZTDFS2ZTN0tvUnHzJI12fGGwdDD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ>	Mn\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
HCC827	NHjCbYpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1XzSVczKGh?		MnXDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1O4Nlch[2WubIOgZZQhOSC3TTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y=	M{LYbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
BAF3	NFq5cnFHfW6ldHnvckBie3OjeR?=		NUK4O25sOiCq		MV7Jcohq[mm2aX;uJI9nKEWJRmKgWFc6OE1xTEi1PHIwSzd7N2OgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFXHSk1qdmS3Y3XkJJJm[2WydH;yJJBpd3OyaH;yfYxifGmxbjDheEAyKHSxIEOgeW0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBGT0Zic4TpcZVt[XSrb36g[o9zKDF3IH3pcpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NXvTbm9FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
BAF3	M3LLeWZ2dmO2aX;uJIF{e2G7		MkTjNkBp		MWPJcohq[mm2aX;uJI9nKEWJRmKgNVlFN1R5OUDNM2M4QTeVIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHR1[tbY5lfWOnZDDy[YNmeHSxcjDwbI9{eGixconsZZRqd25iYYSgNUB1dyB\|IIXNJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgSWdHKHO2aX31cIF1cW:wIH\vdkAyPSCvaX7zJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NFLmXVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
NCI-H1975	NUnJN4tLSW62aYT1cY9zKGGldHn2bZR6KGG\|c3H5				MmXrRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHinbn;ndoFnfGWmIHnuJHNVV0ONLV\vfI4ydnVxTnr1JI52\GVibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDndo94fGhiYYSgNlAhdWdxa3ev[IF6NCCybzDx[EBnd3JiMUSg[IF6eyC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?=	MoPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|OUWyNVkoRjJ6M{m1NlE6RC:jPh?=
Caco2	M1\IW2Z2dmO2aX;uJIF{e2G7		NF;yWpIzKGh?		NG\ZcVJG\m[udYigdoF1cW9ib3[gZZBx[XKnboSgdIVzdWWjYnnsbZR6KG[{b32gZoF{d2yjdHXyZYwhe2mmZTD0c{BieGmlYXygd4ll\SCxdnXyJIFxcWOjbDDzbYRmKHSxIHLhd49t[XSncnHsJJNq\GVib4\ldkBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN?	MmXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
A431	MnvYSpVv[3Srb36gZZN{[Xl?				NEDSbZhU\WynY4Tpeol1gSC{YYTpc{Bw\iCHQ{WwJIZweiCqdX3hckBCPDNzIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnIhfG9iRVO1NEBnd3JiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIhiemKxcnnu[{BGT0[ULVy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnR?	MmLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
Caco2	Ml\ySpVv[3Srb36gZZN{[Xl?		NIDzbpYzKGh?		MkHGRZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{BieGmlYXygeI8h[mG\|b3zheIVz[Wxic3nk[UBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN?	M1LhZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
Caco2	MnLHSpVv[3Srb36gZZN{[Xl?		MmfMNkBp		MnvkRZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{Bj[XOxbHH0[ZJidCC2bzDhdIlk[Wxic3nk[UBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN?	MnvCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
NCI-H1975	M2XBN2Z2dmO2aX;uJIF{e2G7		M{\OVlQhcA>?		MX3Jcohq[mm2aX;uJI9nKEWJRmKgUFg2QFJxVEe5NG0hdXW2YX70JIlvKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iQXv0JJBpd3OyaH;yfYxifGmxbjDheEBVcHJ\|MEivV4VzPDd\|IIPpeIUh[XRiMTD1UUBu\WG\|dYLl[EBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NH7J[lE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	NWn5b3dVTnWwY4Tpc44h[XO\|YYm=		NHzJRXI1KGh?		NUPyRWR6UW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIlvKGi3bXHuJGhESzh{NzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hSWu2IIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhxU3XyOFc{KHOrdHWgZZQhOSC3TTDt[YF{fXKnZDDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	M2TsbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975	MkTERZBweHSxc3nzJIF{e2G7		MYe0PEBp		M2H0TWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBOKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?=	M37LSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	NFfle3BCeG:ydH;zbZMh[XO\|YYm=		NWmxT45mPDhiaB?=		M1;IfGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25ibYX0ZY51KGG\|c3Xzd4VlKGG\|IHPhd5Bie2VvMzDjcIVifmGpZTDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCrbX31co9jdG:2dHnu[y=>	MmDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9	MlHjRZBweHSxc3nzJIF{e2G7		NIG3RVM1QCCq		Mo\HTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBufXSjboSgZZN{\XO\|ZXSgZZMh[2G\|cHHz[U0{KGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK\|IHL5JIludXWwb3Lsc5R1cW6p	Mk\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H3255	M37qRmFxd3C2b4Ppd{Bie3OjeR?=		MkeyOFghcA>?		NFm4PXJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFizNlU2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmNTNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975	NH:3[29CeG:ydH;zbZMh[XO\|YYm=		MVG0PEBp		M4XiTmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBOKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o	NXTQRXdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9	MX7BdI9xfG:\|aYOgZZN{[Xl?		MYW0PEBp		M1i2SWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUFO5JINmdGy\|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIF{e2W\|c3XkJIF{KFCDUmCgZ4xm[X[jZ3WgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliaX3teY5w[myxdITpcoc>	M2nJSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	NVnyZ2xlSXCxcITvd4l{KGG\|c3H5		NWP5PVBEPDhiaB?=		M2rENmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25ibYX0ZY51KGG\|c3Xzd4VlKGG\|IGDBVnAh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd?	M{jlV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255	MXnBdI9xfG:\|aYOgZZN{[Xl?		Mln6OFghcA>?		MYPJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEh\|MkW1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSJI12fGGwdDDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	M2HybFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975	MYTGeY5kfGmxbjDhd5NigQ>?				NU[wZVZMW2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRidH:gTWM2OCCob4KgbJVu[W5iQUSzNUBk\WyuczDoZZJjd3Krbnege4lt\C22eYDlJGVITlJ?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{Nkm5Okc,Ojh2Mk[5PVY9N2F-
human hepatocytes	Mkj4SpVv[3Srb36gZZN{[Xl?				MmmzTY51emmwc3njJINt\WG{YX7j[UBqdiCqdX3hckBp\XCjdH;jfZRmeyCjc4Pld5Nm\CCyZYKgcYltdGmxbjDj[Yxtew>?	M3;wTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
rat hepatocytes	Mn;LSpVv[3Srb36gZZN{[Xl?				M2XzSGlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5icnH0JIhmeGG2b3P5eIV{KGG\|c3Xzd4VlKHCncjDtbYxtcW:wIHPlcIx{	NHW2Sm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
A549, NCI-H1975	NH23N4VHfW6ldHnvckBie3OjeR?=				NF3HO3lU\WynY4Tpeol1gSC{YYTpc{Bw\iCLQ{WwJIZweiCHR1[td5RqdXWuYYTl[EB4cWymIIT5dIUhTUeIUjDpckBpfW2jbjDBOVQ6KGOnbHzzJJRwKEmFNUCg[o9zKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHN?	Mne1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
A549, PC9	NHu5R2FHfW6ldHnvckBie3OjeR?=				M3nT[nNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKEWJRj3zeIlufWyjdHXkJJdqdGRidInw[UBGT0[UIHnuJIh2dWGwIFG1OFkh[2WubIOgeI8hUUN3MDDmc5IhTUeIUjDk[YxmfGmxbjDteZRidnRiaX6gbJVu[W5iUFO5JINmdGy\|	NW\6W3F3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
HCC827	M{Xv[2Fxd3C2b4Ppd{Bie3OjeR?=				M4HUdGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYhfG9iQUe1NEBl\WyndHnvckBufXSjboSgZZN{\XO\|ZXSgZZMh\WG{bImgZZBweHSxdHnjJINmdGy\|IHH0JFMhfU1iYX\0[ZIhOjRiaILzJIJ6KEGwbnX4bY4hXi2ISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpkhMFK4YjC9JFEvOzRidH:gNU43PyVr	Ml;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN\|QxRC:jPh?=
NCI-H1975	MUDGeY5kfGmxbjDhd5NigQ>?				NGKzXmNKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGG2IEGgeI8hOTByIH7NJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R?	NGj3XWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUmwOlEyPCd-Mkm5NFYyOTR:L3G+
A431	MUfGeY5kfGmxbjDhd5NigQ>?				M1T6OHNmdGWldHn2bZR6KHKjdHnvMEBz[XSrbzDJR\|UxKG[xcjDoeY1idiCDNEOxJINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKHerbHSteJlx\SCHR1\SJJRwKEmFNUCg[o9zKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiVEe5NG0wVDh3OGKgcZV1[W62	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MU[zPUc,OjdzM{G2N\|k9N2F-
PC9	M3fxcWFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?=				NY\r[3BbSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gVGM6KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25iYXP0bZZifGmwZzDteZRidnRieHXuc4dz[W[2ZXSgbY4hW0OLRDDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCxNEBu\y:tZz;kZZktKHCxIIHkJIZweiB5IHThfZMhemWuYYTpeoUhfG9iY3;ueJJwdA>?	NF;LW\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
A431	NFXCZVRCdnSrdIXtc5Ih[WO2aY\peJkh[XO\|YYm=				M1nPNWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0N\|Eh[2WubIOgfIVvd2e{YX\0[YQhcW5iU1PJSEBud3W\|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhiaX7obYJqfGmxbjDheEA2KG2pL3vnM4RigSxicH:gdYQh\m:{IEeg[IF6eyC{ZXzheIl3\SC2bzDjc451em:u	NYLZenh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	p-EGFR / p-AKT / p-ERK; PubMed: 28416483 Cancer Res PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib. ABCB1; PubMed: 27649127 Molecules The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.	28416483 27649127
Growth inhibition assay	Cell viability; PubMed: 31043587 Cell Death Dis Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. P < 0.05, P < 0.01, **P < 0.005 by t-test.	31043587
Immunofluorescence	Ki67 / γH2AX / p16; PubMed: 29212784 EMBO Mol Med PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. P ≤ 0.01, *P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.	29212784

体内試験

AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. ^[2]

お薦めの試験操作（参考用のみ）

動物試験： ^[2]	- 合併動物モデル： Mice bearing PC9 and H1975 xenograft tumors 投薬量： ~5 mg/kg 投与方法： p.o. (参考用のみ)

参考

溶解度 (25°C)

体外	DMSO	99 mg/mL (198.15 mM) warming
	Water	Insoluble
	Ethanol	'43 mg/mL warmed '43
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O 混合させたのち直ちに使用することを推奨します。	7.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Osimertinib (AZD9291) SDFをダウンロードする

分子量	499.61
化学式	C₂₈ H₃₃ N₇ O₂
CAS No.	1421373-65-0
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	Mereletinib
Smiles	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02841579	Completed	Drug: Osimertinib	Non-Small Cell Lung Cancer	MedSIR\|AstraZeneca	August 2016	Phase 2
NCT02771314	Active not recruiting	Drug: AZD9291	Non Small Cell Lung Cancer	Hellenic Oncology Research Group	August 2 2016	Phase 2
NCT02511106	Active not recruiting	Drug: AZD9291 80 mg/40 mg\|Drug: Placebo AZD9291 80 mg/40 mg	Stage IB-IIIA Non-small Cell Lung Carcinoma	AstraZeneca	October 21 2015	Phase 3
NCT02529995	Completed	Drug: AZD9291 40 mg\|Drug: AZD9291 80 mg	Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive	AstraZeneca	August 24 2015	Phase 1
NCT02491944	Completed	Drug: AZD9291\|Drug: [14C]AZD9291	Oncology	AstraZeneca	July 2015	Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?
回答：
Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

EGFRシグナル伝達経路

相関EGFR製品

Erlotinib

Erlotinib (CP358774, NSC 718781, OSI-774) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B)

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Lapatinib

Lapatinib (GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.

研究分野別

製品類型

Osimertinib (AZD9291)

文献中Selleckの製品使用例(221)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Osimertinib (AZD9291) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技術サポート

よくある質問（FAQ）

EGFRシグナル伝達経路

相関EGFR製品